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Abstract
Background:  Manic-depression or bipolar disorder (BD) is a multi-faceted illness with an
inevitably complex treatment.
Methods:  This article summarizes the current status of our knowledge and practice of its
treatment.
Results: It is widely accepted that lithium is moderately useful during all phases of bipolar illness
and it might possess a specific effectiveness on suicidal prevention. Both first and second generation
antipsychotics are widely used and the FDA has approved olanzapine, risperidone, quetiapine,
ziprasidone and aripiprazole for the treatment of acute mania. These could also be useful in the
treatment of bipolar depression, but only limited data exists so far to support the use of quetiapine
monotherapy or the olanzapine-fluoxetine combination. Some, but not all, anticonvulsants possess
a broad spectrum of effectiveness, including mixed dysphoric and rapid-cycling forms. Lamotrigine
may be effective in the treatment of depression but not mania. Antidepressant use is controversial.
Guidelines suggest their cautious use in combination with an antimanic agent, because they are
supposed to induce switching to mania or hypomania, mixed episodes and rapid cycling.
Conclusion:  The first-line psychosocial intervention in BD is psychoeducation, followed by
cognitive-behavioral therapy. Other treatment options include Electroconvulsive therapy and
transcranial magnetic stimulation. There is a gap between the evidence base, which comes mostly
from monotherapy trials, and clinical practice, where complex treatment regimens are the rule.
Published: 9 October 2007
Annals of General Psychiatry 2007, 6:27 doi:10.1186/1744-859X-6-27
Received: 5 April 2007
Accepted: 9 October 2007
This article is available from: http://www.annals-general-psychiatry.com/content/6/1/27
© 2007 Fountoulakis et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Annals of General Psychiatry 2007, 6:27 http://www.annals-general-psychiatry.com/content/6/1/27
Page 2 of 12
(page number not for citation purposes)
Background
The term 'bipolar disorder' (BD) is the contemporary
label used for what is widely known as manic depressive
illness, and was described for the first time by Hippocrates
and Areteus. In modern times, Falret defined it as an ill-
ness in 1851. Today, two types are officially recognized,
bipolar disorder type I and type II (BD-I and BD-II), and
combined they account for a 3.7% prevalence rate or
higher [1,2]. Both types constitute disabling conditions.
Treatment aims to the resolution of symptoms, the resto-
ration of psychosocial functioning and the prevention of
relapses.
When collecting scientific data on the treatment of BD,
diagnosis seems to be a problem as it is often retrospective
and carries the risk of bias and memory distortions; hence
it is of questionable reliability and validity.
Another problem is that while a specific treatment may be
effective for the management of a specific cluster of symp-
toms, it may not be effective for the management of other
clusters. Thus, treatment has to be regarded separately for
each type of episode (manic, hypomanic, bipolar depres-
sion) and phase of the disease (acute, long-term and
maintenance).
Double-blind, placebo-controlled studies are the main
source of scientific proof of efficacy for available treat-
ments. These should ideally be two-arm studies, including
both the acute and the long-term (prophylactic or mainte-
nance) phase, extending to a period of up to 6 or 12
months, depending on the investigated subtype. Never-
theless, there are no veracious data concerning all facets of
affective illness.
The comparator agent is also an open issue, as it is still
unclear whether this should be lithium, an antidepres-
sant, an antipsychotic or something else, or whether the
selection of the comparator agent should be based on the
acute or the most recent phase. Likewise, it is still under
consideration whether the ideal concept is that of a five-
arm study, including a placebo and a drug-under-investi-
gation group along with three comparator groups (lith-
ium, antidepressant, antipsychotic). Such a concept of
course is of very high financial cost, thus not yet used. The
inclusion of a placebo group is of major importance [3],
as its lack weakens the evidence; such a design cannot pro-
vide sufficiently accurate data because the underlying pla-
cebo response rate may be substantial and varies across, as
well as within, studies. Furthermore, in the maintenance
phase, the difference between placebo and an active com-
parator needs a follow-up period of at least 6 months, to
be seen.
Another factor which may perplex the design of a clinical
trial and the interpretation of its results is the fact that the
patients' clinical condition and the natural history of the
disease may be influenced by drug discontinuation, espe-
cially lithium discontinuation. This, especially when
abrupt, is reported to elicit mania and lead to a refractory
condition [4,5], thus affecting the results of a study. Age
could be an additional confounding factor, as it may be
responsible for an increased resistance to monotherapy
[6].
Generalization of results is also a major problem. Treat-
ments that are effective for unipolar depression are gener-
ally considered to be effective for bipolar depression as
well, but not vice-versa [7]. Likewise, treatments that are
effective for mania seem to be effective for hypomania as
well, but not vice versa. However there is no sufficient
data to support or reject these assumptions. As far as rapid
cycling is concerned, data regarding the treatment of bipo-
lar disorder in general do not necessarily apply to rapid
cycling.
In this context, the development of treatment guidelines
seems to be a rather important issue, in order to standard-
ize treatment choices and apply research data to everyday
clinical practice, by integrating information from different
sources into easily applicable and accessible algorithms.
The development of algorithms is mainly based on dou-
ble-blind placebo-controlled trials, open studies and ret-
rospective data analyses (experimental data). Expert
opinion and clinical consensus is also taken under consid-
eration, whereas consumer opinion may play an impor-
tant role as well. Unlike earlier stages, which are simpler
and more solidly evidence-based, as algorithms proceed
to later stages, experimental data become ever more insuf-
ficient, resulting to a gradual take-over of expert opinion
or clinical consensus.
Algorithms and guidelines facilitate clinical decision-
making, reduce clinically inappropriate or cost-inefficient
clinical practice decisions, and provide similar treatment
across different settings but also a metric to assess patient
response and a framework to evaluate the cost of treat-
ment. Therefore they seem to be beneficial both for
patients and the health system in general. Nevertheless,
there are several potential problems associated with algo-
rithms [8], e.g., disproportionate increase in cost-benefit
ratio, biased consensus panel opinion, insufficient evi-
dence for the development of an algorithm, poorer stand-
ard of care and inappropriate use due to a rigid, difficult
to follow algorithm, sues for malpractice on the ground of
deviation from an algorithm, etc.
The aim of this article is to summarize the contemporary
knowledge and current practice concerning the treatmentAnnals of General Psychiatry 2007, 6:27 http://www.annals-general-psychiatry.com/content/6/1/27
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of bipolar disorder, by performing a selective review of the
literature.
Existing treatment guidelines for bipolar disorder
To date, several papers about treatment guidelines for
bipolar disorder have been published [8-40]. There are
also a number of guideline documents developed by
national bodies that have been published. The CANMAT
[37] and the NICE [34] guidelines are the most recent, but
even they fail to incorporate all recent findings and
approvals [41].
The gradual acceptance of the use of atypical antipsychot-
ics such as monotherapy and of antidepressants for a lim-
ited period of time, and in combination with antimanic
agents, seems to be the trend [42]. A summary of guide-
lines is shown in Table 1.
Lithium
It is generally accepted and supported by the literature
that lithium is moderately useful against all phases of BD.
It is also believed to exert a specific action on suicide pre-
vention [36,43-50] and its use is strongly endorsed by all
published treatment guidelines [42]. It seems to be a
somewhat more effective against classic mania (the
response rate being around 40%) than against depression
[36,39,51,52]. It has a relatively slow onset of action; clin-
Table 1: Guidelines for the treatment of bipolar disorder
Acute mania Acute bipolar depression Maintenance
TMAP, 2002 First step:
Li, Vp, Olz
Second step:
Various combinations of two first 
choice agents
First step:
Li, Vp, Olz, Li/Vp/Olz + SSRI/La
Second step:
Various combinations of two or more 
first choice agents, ECT
First step:
Li, Vp, Olz, monotherapy or +AD 
(intermittent use)
Second step:
Various combinations of two or more 
first choice agents
WFSBP, 2003 First step:
Li, Vp, Olz, Ris, Cbz
Second step:
Combinations of MS+aAPs, ECT
First step:
AD+MS, SSRIs + Li/La/Vp/Cbz
Second step:
Combination of first choice agents, 
augmentation strategies, ECT
First step:
After depression:
AD+MS, SSRIs + Li/La/Vp/Cbz After 
mania: Li, MS, AP
Second step:
Combination of first choice agents
APA, 2002 and 2007 First step:
Severe: Li/Vp+AP
Mild-Moderate: Li, Vp, Olz
Second step:
Various combinations of two first 
choice agents, ECT
2007 update:
Li for classic mania, Vp for mixed 
episodes, Cbz, Olz, Li/Vp+AP, ECT
First step:
Li, La, Li+AD, ECT
Second step:
Various combinations of two first 
choice agents, ECT
2007 update:
Li, Vp, La, MAOIs, SSRIs, Venf, TCAs, 
OFC, ECT
First step:
Li, Vp, possibly Cbz, La, Ocbz. 
Continue the treatment proved 
efficient during the acute phase
Second step:
ECT, combination of first choice 
agents. AP should be discontinued
2007 update:
Li, Vp, La, ECT
CANMAT, 2007 First step:
Li, Vp, Olz, Ris, Quet, Arip, Zip, Li/
Vp+Ris/Quet/Olz
Second step:
Cbz, Ocbz, ECT, Li+Vp
Third step:
Hal, Clpz, Li/Vp+Hal, Li+Cbz, Cloz
First step:
Li, La, Li/Vp+SSRI, Olz+SSRI, Li/
Vp+Bupr, Quet
Second step:
Quet+SSRI, Li/Vp+La
Third step:
Cbz, Olz, Vp, Li+Cbz, Li+Pramx, Li/
Vp+Venf, Li+MAOI, ECT, Li/Vp/
AAP+TCA, Li/Vp/Cbz+SSRI+La, 
adjunctive EPA/riluzole/topiramate
First step:
Li, La, Vp, Olz
Second step:
Cbz, Li+Vp/Cbz, Li/Vp+Olz, Arip, Ris, 
Quet, Zip, Li+Ris/Quet, Li+La/SSRI/
Bupr, OFC
Third step:
Adjunctive flupenthixol, gabapentin, 
topiramate, AD
NICE, 2006 First step:
Severe: Olz, Quet, Ris. Li/Vp only in 
patients that previously responded to 
these agents. BZ if necessary Milder 
forms: Li/Vp
Second step:
Li/Vp+APP
Third step:
ECT
First step:
SSRI+AM
Second step:
SSRI+Li/Vp+Quet, Mrz/Venf+AM
Third step:
ECT
First step:
Discontinuation of Ads, keep Li/Olz/Vp
Second step:
Combinations of first step agents
Third step:
Combinations of first step agents plus 
La/Cbz
AAPs, atypical antipsychotics; AD, antidepressants; AM, antimanic agents; APs, antipsychotics; Arip, aripiprazole; BZ, benzodiazepines; Bupr, 
Buproprione; Cbz, carbamazepine; ECT, electroconvulsive therapy; EPA, eicosapentaenoic acid; La, lamotrigine; Li, lithium; MAOI, monoamine 
oxidase inhibitor; Mrz, mirtazapine; MS, mood stabilizers; Ocbz, oxcarbazepine; OFC, Olanzapine-fluoxetine combination; Olz, olanzapine; Quet, 
quetiapine; Ris, risperidone; SSRIs, Selective Serotonine Reuptake Inhibitors; TCA, Tricyclic antidepressant; Venf, venlafaxine; Vp, valproic; Zip, 
ziprasidone.Annals of General Psychiatry 2007, 6:27 http://www.annals-general-psychiatry.com/content/6/1/27
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ical improvement generally occurs within 1 to 3 weeks of
treatment.
A potential problem may be that after several years of suc-
cessful use, a number of patients seem to develop a toler-
ance to lithium, while up to 15% of patients report a
lithium discontinuation-induced refractoriness [53].
Resistance to lithium treatment could be predicted by the
presence of mixed or dysphoric mania, rapid cycling,
many prior episodes, poor interepisode functioning, an
episode pattern of depression-mania-euthymia, comorbid
substance abuse, and comorbid personality disorder
[5,54]. By contrast, patients with an episodic course with
euthymic intervals and the absence of rapid cycling may
be better responders.
The recommended therapeutic Li blood levels for the
treatment of acute mania range from 0.6–1.2 mEq/L,
whereas maintenance levels could be lower, ranging from
0.6 to 0.9 mEq/L. Levels higher than 1.2 mEq/L are poten-
tially toxic. When treating a patient with lithium, creati-
nine clearance is regarded to be the most reliable marker
of kidney function to take into consideration.
Adverse events are to be expected during treatment with
lithium [55], the most frequent being neurological, endo-
crinological (usually concerning the thyroid), cardiovas-
cular, renal, gastrointestinal, hematological and
dermatological manifestations and lithium intoxication.
However, only about 30% of patients have more than
minor complaints, whereas less than 20% of have no
adverse effects at all.
Anticonvulsants
While lithium seems to be more specific to euphoric
mania, specific anticonvulsants (but not all) seem to have
a broad spectrum of effectiveness, including mixed, dys-
phoric and rapid-cycling forms.
Valproic acid is FDA approved for the treatment of acute
manic episodes. Its response rate in acute mania is around
50%, compared to a placebo effect of 20–30% [48,54,56-
63]. Patients respond relatively rapidly (within 1–2 weeks
and often a few days). Valproate appears to have a more
robust antimanic effect than lithium in rapid cycling and
mixed episodes [63,64]. Concerning bipolar depression,
there is only one controlled study supporting the effective-
ness of valproate [57], whereas uncontrolled data suggest
that it may be less effective than against mania (response
rate close to 30%) [57,65]. Although valproate seems to
have significant prophylactic antimanic properties, its
prophylactic antidepressant ones are low-to-moderate
[65-67]. Therapeutic serum levels range between 50 and
150 mg/mL. Gastrointestinal symptoms, sedation,
tremor, weight gain, hair loss, ataxia, dysarthria and per-
sistent elevation of hepatic transaminases are among its
common adverse effects.
Carbamazepine is approved by the FDA only for the treat-
ment of bipolar mania. It is widely used, especially in con-
tinental Europe. The response rate against acute mania is
close to 50% (similar to that of valproic) [68-71]. How-
ever, the response rate against bipolar depression appears
to be lower (roughly 30% or less) [72,73]. Car-
bamazepine seems to be less effective in the prophylaxis
against depressive than against manic/mixed episodes
[69] and less effective than lithium [74-81]. The MAP
study in 1997 [81,82] and a replication in 2003 [74] are
the most important among studies comparing car-
bamazepine and lithium. Both studies showed a superior-
ity of lithium over carbamazepine for the treatment of
classic mania. A secondary analysis of the MAP data dem-
onstrated that patients that don't respond to lithium may
have a favourable response to carbamazepine [77],
although its actual long-term efficacy is under question.
The recommended dosage against acute mania is 600–
1800 mg daily (blood concentration 4–12 mg/mL).
Hepatic enzymes (CYP 3A4) induction occurs after several
weeks, resulting to a lowering of drug levels. This may
require additional upward dose titration [83]. Adverse
effects are dose-related and include double or blurred
vision, dizziness, sedation, ataxia, and diplopia, vertigo,
gastrointestinal disturbances, cognitive impairment and
hematological effects [5,84,85]. The induction of the
metabolism of antidepressants, antipsychotics and other
anticonvulsants is yet another major problem which
makes the use of carbamazepine during combination
treatment problematic.
Lamotrigine, at a daily dosage of 50–200 mg may be effec-
tive in the treatment of acute bipolar depression but not
mania [45,86-93]. Moreover, it may be equally effective to
lithium in the prophylaxis of any mood episode [22,45].
In depression, response rates are double than those
observed under placebo (close to 50%). Lamotrigine may
also be effective against rapid cycling [54]. Treatment
should be initiated slowly; 25 mg daily for the first 2
weeks and then 50 mg for another 2 weeks, followed by
slow increases, in order to avoid a moderately high inci-
dence of rash.
Topiramate and gabapentin can only be used as supple-
mentary therapy for the treatment of weight gain (topira-
mate) and anxiety (gabapentin), as data on them is
negative [94-97]. Data regarding other anticonvulsants is
not reliable. It must be pointed out that unlike antipsy-
chotics, that seem to have a possibly antidopaminergic
'class effect' limited to the treatment of acute mania, anti-
convulsants have no such effect in any phase of bipolarAnnals of General Psychiatry 2007, 6:27 http://www.annals-general-psychiatry.com/content/6/1/27
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disorder. Each agent has a very distinct pharmacologic
profile, thus should be considered separately.
Antipsychotics
First generation (typical) antipsychotics (FGAs) are con-
sidered to be the traditional first-line treatment for acute
mania, especially in Europe. TGAs, mostly haloperidol,
have been used for long and are generally regarded to act
faster than mood stabilizers. Nevertheless, many psychia-
trists share the anecdotal clinical impression that FGAs
induce depression.
Unlike FGAs, second generation (atypical) antipsychotics
(SGAs) do not induce depression. Moreover, several
recent studies support their usefulness in all phases of
bipolar illness, either as monotherapy or as an adjunct to
conventional mood stabilizers. They have a lower inci-
dence of extrapyramidal symptoms and signs, thus con-
sidered to have a more favourable adverse effects profile.
Improvement is reported to be similar among different
antipsychotic agents, irrespective of whether the antipsy-
chotic was utilized as monotherapy or adjunctive therapy
[98]. Olanzapine, risperidone, quetiapine, ziprasidone
and aripiprazole have already been approved by the FDA
for the treatment of acute mania. These drugs are also
approved for the treatment of mania in most European
countries. Although available data is still limited, SGAs
are considered a rather promising option for treating
bipolar depression.
The use of adjunct SGAs on anticonvulsants produces a
response rate increase of about 20%, while, when used as
monotherapy, SGAs produce a roughly 20% difference
from placebo.
Risperidone effectiveness in acute mania is supported in
several studies [99] with remission rates of 42% vs 13%
for placebo [85,100-107]. Dose-related extrapyramidal
symptoms, weight gain, sedation and hyperprolactinemia
seem to be its main disadvantages [99]. There are also a
number of studies that included patients with mixed
states [101,102,106].
Olanzapine has the highest number of published rand-
omized control trials (RCTs) [1,60,85,87,108-128] and a
solid basis supporting its use in bipolar disorder [129],
hence it is the most well-studied atypical antipsychotic. It
is approved by the FDA, but not the EMEA, for the treat-
ment of bipolar depression (only in combination with
fluoxetine), and for the maintenance phase for those
patients that responded well to olanzapine during an
acute manic episode [118,122,130]. Regarding mixed epi-
sodes, there are some available data, however its use is not
well established. The most common adverse effects
reported include dry mouth, weight gain, increased appe-
tite and somnolence [60].
Quetiapine effectiveness in both mania and depression as
monotherapy is supported by RCTs [59,69,131-139]. It is
currently the only SGA approved by the FDA as a mono-
therapy (300–600 mg/daily) for both acute mania and
bipolar depression. In depression trials, 600 mg/day were
found not to be more effective than 300 mg/day. Con-
cerning mixed episodes and rapid cycling, only some
uncontrolled data is available [21,135]. The most com-
mon adverse effects include somnolence and hypoten-
sion.
The use of aripiprazole and ziprasidone as monotherapy
in manic or mixed episodes is supported by existing data
[42,140-144]. The most common adverse events are aka-
thisia (Aripiprazole), somnolence and extrapyramidal
symptoms (Ziprasidone).
Antidepressants
Currently, fluoxetine, as part of the fluoxetine plus olan-
zapine combination, is the only antidepressant medica-
tion officially approved by the FDA for the treatment of
bipolar depression [87,112,126].
In spite of the fact that there are some double-blind stud-
ies supporting their effectiveness against bipolar depres-
sion [145-147], this is still an open issue. Thus, their use
and usefulness in bipolar disorder is still controversial
[102]. Guidelines suggest their cautious use, always in
combination with an antimanic agent [139], as antide-
pressants may induce switching to mania or hypomania,
mixed episodes and rapid cycling [148-151]. In patients
receiving a mood stabilizer, the outcome of depression
could be improved by the addition of an antidepressant
without significantly altering the risk of switch [152].
According to earlier studies, switching to mania or hypo-
mania was a considerable risk, especially with tricyclics
[46,153]. However, this may not apply to newer agents.
Switching to mania or hypomania may occur in 7–30% of
patients. This depends on the antidepressant agent and
dose used and the personal (prepubertal onset) and fam-
ily history [154,155]. Nevertheless, it is supported by
some authors that the true rate of switching is rather low,
if any [154,156-158]. The general concept however, is that
dual action agents (TCAs or Serotonin and Noradrenaline
Reuptake Inhibitors – SNRIs) may be more potent in
increasing the risk for switching to mania or hypomania
[148,159] and to development of suicidal ideation
[38,160,161]. An adjunctive antimanic agent (atypical
antipsychotic or anticonvulsant) may protect against
switching or mixed symptoms, but this is not always the
case [148,162].Annals of General Psychiatry 2007, 6:27 http://www.annals-general-psychiatry.com/content/6/1/27
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A warning regarding the possible induction of suicidality
(ideas and behavior but not completed suicide) by antide-
pressants in children and adolescents and possibly in all
age groups, has been recently issued by the FDA [163],
however data from the STEP-BD program does not sup-
port the idea of increased suicidality in bipolar patients
treated with antidepressants [164]. Thus, this issue
remains controversial.
Psychotherapy and other non-pharmacological therapies
Hard data concerning the effectiveness of psychosocial
interventions in BD are emerging. Psychoeducation is
what appears to be the first line of psychosocial interven-
tion. In bipolar patients under medication, psychoedua-
tion, family-focused psychoeducation and cognitive-
behavioral therapy seem to be the most efficacious inter-
ventions for relapse prevention. Moreover, they can help
both the patient and family members to learn to recognize
early warning signs of oncoming episodes, thus obtain
earlier treatment interventions, and to identify possible
triggering factors [165].
Although there are no definite data, the efficacy of electro-
convulsive therapy (ECT) in acute mania is supported by
several older clinical observations and some more recent
clinical trials [166-168]. Transcranial magnetic stimula-
tion (rTMS) of the brain at 20 Hz over the right but not left
frontal cortex or 1 Hz bi-frontally is reported to be effec-
tive, however data are still insufficient and no conclusions
can be drawn [169-171].
Discussion
Previously, there has been an obvious discrepancy
between recommendations made by opinion leaders and
researchers and decisions made by clinicians in everyday
practice. This discrepancy appeared to depict the different
approaches to bipolar disorder in US and Europe, and,
although today it is significantly smaller, somehow it still
exists.
Treatment guidelines strongly emphasize monotherapy
during the first stage of treatment algorithms. However,
reality proves that this first stage is practically useless or
that clinicians do not seem to appreciate it. Statistics show
that the vast majority of BD patients receive more than
one medication, with a significant percentage receiving
three or more. Only 5–10% of patients are on mono-
therapy, whereas half may receive at least three different
agents [172,173]. Therefore, recently, combination ther-
apy is gaining ground even in treatment guidelines [36].
A comprehensive evaluation of the data concerning the
various treatment modalities against the different facets of
BD is shown in Table 2. The literature suggests that proper
treatment of BD patients needs continuous administra-
tion of an antimanic agent [42], but this may be one of the
Table 2: Grading of data on the basis of a modified POST method
Agent/modality Acute mania Acute bipolar depression Maintenance treatment
Amisulpride + ND +
Aripiprazole ++++ - +++
Benzodiazepines + ND ND
Carbamazepine ++++ ++ +++
Citalopram ND + +
Clozapine ++ ND ++
ECT ++ +++ +
Fluoxetine ND ++++ ++
Gabapentin - - ++
Lamotrigine - ++++ ++++
Lithium ++++ ++++ ++++
Olanzapine ++++ +++ ++++
Olanzapine-fluoxetine combination ND ++++ ++
Quetiapine ++++ ++++ ND
Risperidone ++++ ND ND
Topiramate - + ND
Valproiate ++++ +++ +++
Ziprasidone ++++ ND ND
Psychoeducation ND ND ++++
TMS ND ND ND
++++, good research-based evidence, supported randomized placebo-controlled and comparison trials; +++, fair research-based evidence, 
supported by randomized controlled trials but there are some drawbacks (small sample size or no placebo control); ++, some evidence on the basis 
of at least one small scale RCT; +, Recommendation based on prospective case studies, or large scale retrospective chart analyses and support by 
expert opinion; -, negative data; ND, no data.Annals of General Psychiatry 2007, 6:27 http://www.annals-general-psychiatry.com/content/6/1/27
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reasons why depression predominates in the course of
bipolar disorder.
Against acute mania, SGAs might act faster and better than
lithium and anticonvulsants while their efficacy during
the maintenance phase may be comparable. Quetiapine
and the olanzapine plus fluoxetine combination have
proven efficacy against both mania and bipolar depres-
sion. An SGA alone could be enough to control the dis-
ease manifestations in patients with a history of
predominant manic or mixed episodes and rare and short
depressive episodes [174]. Adding lamotrigine and
increase it slowly up to 200 mg daily could help in con-
trolling depressive symptoms. Antidepressants (mainly
SSRIs), if needed, should be initiated at a low dosage with
careful titration [34]. Other options for treatment-resist-
ant patients include MAOIs, and ECT. Some authors sug-
gest that after the second episode of bipolar illness, long
term treatment is necessary and it has been claimed that
maintenance treatment should last at least 2 years after an
episode or 5 years if the patient has risk factors for relapse
[34], however in clinical practice it is better to plan for life-
time treatment unless contraindications or specific issues
argue against it.
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